Follow
Ola Caster
Ola Caster
Olink
Verified email at olink.com
Title
Cited by
Cited by
Year
Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century
S Watson, O Caster, PA Rochon, H den Ruijter
EClinicalMedicine 17, 100188, 2019
2312019
Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®
RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén
Drug Safety 40 (1), 81-90, 2017
1172017
Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations
O Caster, Y Aoki, LM Gattepaille, B Grundmark
Drug Safety 43, 479-487, 2020
1142020
The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models
J Ribbing, J Nyberg, O Caster, EN Jonsson
Journal of pharmacokinetics and pharmacodynamics 34 (4), 485-517, 2007
1092007
Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank
O Caster, K Juhlin, S Watson, GN Norén
Drug Safety 37 (8), 617-628, 2014
1082014
Large‐scale regression‐based pattern discovery: The example of screening the WHO global drug safety database
O Caster, GN Norén, D Madigan, A Bate
Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010
972010
Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR
J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ...
Drug Safety 42, 1393-1407, 2019
942019
Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project
O Caster, J Dietrich, ML Kürzinger, M Lerch, S Maskell, GN Norén, ...
Drug safety 41, 1355-1369, 2018
672018
Earlier discovery of pregabalin’s dependence potential might have been possible
O Caster, IR Edwards, GN Norén, M Lindquist
European journal of clinical pharmacology 67 (3), 319-320, 2011
502011
Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance
GN Norén, O Caster, K Juhlin, M Lindquist
Drug safety 37 (9), 655-659, 2014
452014
vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real‐world use
O Caster, L Sandberg, T Bergvall, S Watson, GN Norén
Pharmacoepidemiology and Drug Safety 26 (8), 1006-1010, 2017
392017
Characteristics, quality and contribution to signal detection of spontaneous reports of adverse drug reactions via the WEB-RADR mobile application: a descriptive cross …
I Oosterhuis, H Taavola, PM Tregunno, P Mas, S Gama, V Newbould, ...
Drug safety 41, 969-978, 2018
382018
Reporting Patterns Indicative of Adverse Drug Interactions
J Strandell, O Caster, A Bate, N Norén, IR Edwards
Drug safety 34 (3), 253-266, 2011
382011
The development and evaluation of triage algorithms for early discovery of adverse drug interactions
J Strandell, O Caster, J Hopstadius, IR Edwards, GN Norén
Drug safety 36 (5), 371-388, 2013
362013
Reflections on attribution and decisions in pharmacovigilance
O Caster, IR Edwards
Drug safety 33, 805-809, 2010
252010
Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance
O Caster, A Conforti, E Viola, IR Edwards
European journal of clinical pharmacology 70 (4), 501-503, 2014
212014
Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a …
L Rolfes, F van Hunsel, O Caster, H Taavola, K Taxis, E van Puijenbroek
British Journal of Clinical Pharmacology 84 (7), 1514-1524, 2018
202018
Logistic regression in signal detection: another piece added to the puzzle.
O Caster, GN Norén, D Madigan, A Bate
Clinical Pharmacology & Therapeutics 94 (3), 2013
192013
Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome
YS Low, O Caster, T Bergvall, D Fourches, X Zang, GN Norén, I Rusyn, ...
Journal of the American Medical Informatics Association 23 (5), 968-978, 2016
172016
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
O Caster, IR Edwards
BMC Neurology 15 (1), 206, 2015
162015
The system can't perform the operation now. Try again later.
Articles 1–20